2020 Medicinal Chemistry Reviews

Volume 55
Joanne J. Bronson, Editor-In-Chief

Medicinal Chemistry Reviews is an outstanding 830 page volume providing timely and critical reviews of important topics in medicinal chemistry. It is provided free of charge to MEDI members in electronic format. Members can also order a print copy, for the cost of printing, shipping and handling ($40 to US addresses, $85 international) at our secure e-commerce site.

Members: To access your electronic copy:

--Click 'Member Login' in the upper right corner of this page
--On the Member Login page, click the 'Resources' tab.

Nonmembers, libraries and institutions wishing to purchase a copy may visit our secure e-commerce site and purchase at non-member prices.

You may also purchase electronic copies of individual chapters at our secure e-commerce site.

Table of Contents:

Chapter 1

Drug Discovery: Ingenuity and Serendipity...Or is It the Other Way Around?
Richard B. Silverman

Chapter 2

The Making of a Drug-Hunting Addict
Scott A. Biller

Chapter 3

Recent Progress in Neuroinflammatory Drug Targets
David P. Rotella

Chapter 4

Recent Progress in Kappa and Mu Opioid Receptor Targeted Ligands
Michael W. Miller, Brian Reed

Chapter 5

Engineered Heart Tissue: An Emerging Paradigm for Early Drug Screening
Matthew J. Robeson, Kristin M. French

Chapter 6

Modulation of Soluble Guanylate Cyclase for the Treatment of Heart Failure and Related Cardiovascular Diseases
Christopher R. Jamison, Andrew K. Dilger

Chapter 7

Recent Advances in the Discovery of NLRP3 Inflammasome Inhibitors
David Harrison

Chapter 8

Advances in the Discovery and Development of Non-Covalent and Covalent BTK Inhibitors Targeting Autoimmune Diseases
Scott H. Watterson and Joseph A. Tino

Chapter 9

TLR7, TLR8, and TLR9 Antagonists: Potential Therapies for Autoimmune Diseases
Lynn D. Hawkins

Chapter 10

Clinical and pre-clinical approaches to the inhibition of KRASG12C
Brian A. Lanman, Victor J. Cee, Matthew A. Marx

Chapter 11

Allosteric Inhibition of SHP2 Phosphatase
Matthew J. LaMarche

Chapter 12

The Development of Tropomyosin Receptor Kinase (Trk) Inhibitors as Targeted Cancer Therapeutics
Abhijit Bhat, Stephane Ciblat, Hong Wang, Kollol Pal

Chapter 13

Recent Progress in the Discovery and Clinical Application of Small-Molecule Inhibitors EZH2 and EED
Julian R. Levell

Chapter 14

Quorum Sensing in Polymicrobial Infections: Analysis of Existing Small Molecule Modulators
Nadezhda A. German

Chapter 15

Drug Target Residence Time and the Pharmacodynamics of Antibacterial Agents
Sneha Basak, Peter J. Tonge

Chapter 16

The Drug Substances of Long-Acting Injectables: Examples from Hormone, CNS, and Antiviral Therapies
Ana Z. Gonzalez, Scott V. Jermain, Ezra B. Roberts, Gregg M. Schwarzwalder

Chapter 17

Targeting Nuclear Export for Treatment of Cancers and Other Diseases
Hanmo Zhang, Dejan Maglic

Chapter 18

Proteasome Activation to Restore Protein Trafficking: A Different Perspective on the Ubiquitin-Proteasome System
Bhaumik A. Pandya, Stephen J. Wood

Chapter 19

RNA-Modifying Enzymes and Their Inhibitors
Wesley Peter Blackaby, Byron Andrews, Beth Thomas, David Hardick, Eric A. Miska

Chapter 20

Recent Developments in IKB Kinases IKK-ε and Tank-Binding Kinase 1 (TBK1) Modulators
Amit A. Joharapurkar, Vrajesh B. Pandya, Mukul R. Jain, Ranjit C. Desai

Chapter 21

Design Strategies for Second-Generation Irreversible Covalent Inhibitors of Bruton’s Tyrosine Kinase
Hui Qiu, Momar Toure, Rebecca L. Casaubon, Maria C. DiPoto, Roland Grenningloh, Richard D. Caldwell

Chapter 22

Therapeutic Degradation of Protein Kinases Through PROTACs: Current Status and Future Potential
Li Zhang, Campbell McInnes

Chapter 23

DNA-Encoded Libraries in the Pharmaceutical Industry
Alexander L. Satz, Christopher S. Kollmann, Brian M. Paegel

Chapter 24

Case History: Tpoxx® (Tecovirimat)—A Novel Orthopoxvirus Egress Inhibitor for the Treatment of Smallpox
Robert Jordan, Doug Grosenbach, James Burgeson, Dennis Hruby

Chapter 25

Case History: Eucrisa® (Crisaborole Ointment, 2%), A Boron-Based PDE4 Inhibitor for the Topical Treatment of Atopic Dermatitis
Matthew A. Perry

Chapter 26

New Chemical Entities Entering Phase III Trials in 2019
Matthew L. Condakes, Anna E. Hurtley, David W. Lin, Gregory T. Notte, Vickie Tsui, Nathan E. Wright, Alec H. Christian

Chapter 27

To Market, to Market—2019: Small Molecules
Erika Araujo, Catherine A. Bolger, Marie-Gabrielle Braun, Georgette Castanedo, Mingshuo Zeng, Adam K. Charnley, Antonella Converso, Izzat T. Raheem, Anthony J. Roecker, Akshay A. Shah, T. G. Murali Dhar, Denise C. Grünenfelder, J. Robert Merritt, Kevin M. Peese

Chapter 28

To Market, to Market—2019: Macromolecular Therapeutics
Nicholas J. Agard, Peter S. Dragovich, Allison M. Beal, Catherine A. Bolger, Suzana A. Kahn, Brant Hubbard, Daša Lipovšek

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org